Imunon, Inc.

Contributing Author

Recent Articles by Imunon, Inc.

Nov-13	IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update IMNN GlobeNewswire
Nov-10	IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer IMNN GlobeNewswire
Nov-10	IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer IMNN GlobeNewswire
Nov-07	IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment IMNN GlobeNewswire
Nov-06	IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025 IMNN GlobeNewswire
Nov-04	IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer IMNN GlobeNewswire
Oct-30	IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting IMNN GlobeNewswire
Oct-23	IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting IMNN GlobeNewswire
Oct-20	IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer IMNN GlobeNewswire
Oct-17	IMUNON Invited to Present PlaCCine DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences IMNN GlobeNewswire
Oct-14	IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress IMNN GlobeNewswire
Sep-22	IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift IMNN GlobeNewswire
Sep-19	IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research IMNN GlobeNewswire
Sep-02	IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference IMNN GlobeNewswire
Aug-28	IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement IMNN GlobeNewswire
Aug-05	IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call IMNN GlobeNewswire
Aug-05	IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update IMNN GlobeNewswire
Jul-30	IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer IMNN GlobeNewswire
Jul-29	IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025 IMNN GlobeNewswire
Jul-28	IMUNON Announces Stock Dividend Boosting Shareholder Value IMNN GlobeNewswire
Jul-23	IMUNON Announces Reverse Stock Split IMNN GlobeNewswire
Jul-15	IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan IMNN GlobeNewswire
Jun-30	IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq's Listing Requirement, Anticipates Additional Compliance Period IMNN GlobeNewswire
Jun-18	IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 IMNN GlobeNewswire
Jun-17	IMUNON Announces PlaCCine DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development IMNN GlobeNewswire
Jun-05	IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th IMNN GlobeNewswire
Jun-03	IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study IMNN GlobeNewswire
Jun-02	IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS IMNN GlobeNewswire
May-28	IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules IMNN GlobeNewswire
May-27	IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 IMNN GlobeNewswire
May-23	IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules IMNN GlobeNewswire
May-23	IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer IMNN GlobeNewswire
May-22	IMUNON Announces Withdrawal of Form S-1 Registration Statement IMNN GlobeNewswire
May-15	IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19 IMNN GlobeNewswire
May-12	IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update IMNN GlobeNewswire
May-08	IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer IMNN GlobeNewswire
May-06	IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology IMNN GlobeNewswire
May-05	IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025 IMNN GlobeNewswire

Imunon, Inc.

Recent Articles by Imunon, Inc.

Upgrade your FINVIZ experience